<DOC>
	<DOCNO>NCT01018368</DOCNO>
	<brief_summary>The objective study evaluate effect multiple dos rifampin single-dose pharmacokinetics VX 770 .</brief_summary>
	<brief_title>Study VX-770 Rifampin Healthy Male Subjects</brief_title>
	<detailed_description>This single-center , nonrandomized , open-label , 2-period , 1-sequence crossover study investigate safety , tolerability pharmacokinetics VX 770 administer alone rifampin . All enrolled subject receive treatment undergo procedure . In Period 1 , subject receive single dose VX 770 Day 1 . In Period 2 , subject receive daily dose rifampin Days 1 10 single dose VX 770 Day 6 .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Subject must male 18 55 year age Subject must body mass index ( BMI ) 18 30 kg/m2 History illness condition , opinion investigator might confound result study pose additional risk administer study drug subject Subjects active tuberculosis , human immunodeficiency virus , hepatitis C , active hepatitis B</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>